Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 29 citing articles:

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.
Nature (2021) Vol. 592, Iss. 7854, pp. 450-456
Open Access | Times Cited: 925
Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review
Ben Sprangers, Leonardo V. Riella, Daan Dierickx
American Journal of Kidney Diseases (2021) Vol. 78, Iss. 2, pp. 272-281
Open Access | Times Cited: 54
Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma
Julia García-Reyero, Nerea Martı́nez, Sonia González de Villambrosía, et al.
Haematologica (2020) Vol. 106, Iss. 4, pp. 1120-1128
Open Access | Times Cited: 51
Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma
Jingjing Guo, Saixia Wang, Yujing Han, et al.
Oncology Letters (2021) Vol. 22, Iss. 1
Open Access | Times Cited: 38
SOX11, CD70, and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma
Patricia Balsas, Luis Veloza, Guillem Clot, et al.
Blood (2021) Vol. 138, Iss. 22, pp. 2202-2215
Open Access | Times Cited: 34
Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorders after Hematopoietic Stem Cell Transplantation: Pathogenesis, Risk Factors and Clinical Outcomes
Ayumi Fujimoto, Ritsuro Suzuki
Cancers (2020) Vol. 12, Iss. 2, pp. 328-328
Open Access | Times Cited: 34
Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma
Paola Chabay
Cancers (2021) Vol. 13, Iss. 11, pp. 2717-2717
Open Access | Times Cited: 27
Biological Difference Between Epstein–Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact
Valeria Ferla, Francesca Gaia Rossi, Maria Goldaniga, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 32
Tumor-associated macrophages in lymphoma: From mechanisms to therapy
Xingfang Xiong, Xiaoli Xie, Zhiqiang Wang, et al.
International Immunopharmacology (2022) Vol. 112, pp. 109235-109235
Closed Access | Times Cited: 18
Intravascular Large B-Cell Lymphoma Genomic Profile Is Characterized by Alterations in Genes Regulating NF-κB and Immune Checkpoints
Blanca González‐Farré, Joan E. Ramis-Zaldivar, Natalia Castrejón de Anta, et al.
The American Journal of Surgical Pathology (2022) Vol. 47, Iss. 2, pp. 202-211
Open Access | Times Cited: 18
Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus–associated Malignant Lymphomas and Lymphoproliferative Disorders
Ayako Kume, Aya Shinozaki‐Ushiku, Akiko Kunita, et al.
The American Journal of Surgical Pathology (2022) Vol. 46, Iss. 10, pp. 1386-1396
Closed Access | Times Cited: 12
Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance
Kevin E. Fisher, Lizmery Suarez Ferguson, Amy Coffey, et al.
Haematologica (2022) Vol. 107, Iss. 8, pp. 1880-1890
Open Access | Times Cited: 10
Epstein-Barr virus-associated posttransplant lymphoproliferative disorders: new insights in pathogenesis, classification and treatment
Daan Dierickx, Martyna Pociupany, Yasodha Natkunam
Current Opinion in Oncology (2022) Vol. 34, Iss. 5, pp. 413-421
Closed Access | Times Cited: 10
Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment
Sanam Shahid, Susan E. Prockop
Cancer Drug Resistance (2021)
Open Access | Times Cited: 14
Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma
John Apostolidis, Ayman Sayyed, Mohammed Darweesh, et al.
Journal of Immunology Research (2020) Vol. 2020, pp. 1-18
Open Access | Times Cited: 13
Human Herpesvirus and the Immune Checkpoint PD-1/PD-L1 Pathway: Disorders and Strategies for Survival
Takayuki Murata
Microorganisms (2021) Vol. 9, Iss. 4, pp. 778-778
Open Access | Times Cited: 11
Genetic and immunological features of immune deficiency and dysregulation‐associated lymphoproliferations and lymphomas as a basis for classification
Daan Dierickx, Colm Keane, Yasodha Natkunam
Histopathology (2024)
Closed Access | Times Cited: 1
Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas
Karolina Bednarska, Karthik Nath, William Nicol, et al.
Blood Reviews (2021) Vol. 50, pp. 100832-100832
Open Access | Times Cited: 10
HHV8-positive, EBV-positive Hodgkin lymphoma-like large B cell lymphoma: expanding the spectrum of HHV8 and EBV-associated lymphoproliferative disorders
Sandra Sanchez, Luis Veloza, Luojun Wang, et al.
International Journal of Hematology (2020) Vol. 112, Iss. 5, pp. 734-740
Open Access | Times Cited: 10
Epstein–Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma
O. Jimenez, Sandra Colli, Mercedes García Lombardi, et al.
Cancer Immunology Immunotherapy (2020) Vol. 70, Iss. 6, pp. 1519-1526
Open Access | Times Cited: 9
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
Yi Que, Yang Hu, Dong‐Chun Hong, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 9, pp. e002920-e002920
Open Access | Times Cited: 9
Insights into intricacies of the Latent Membrane Protein-1 (LMP-1) in EBV-associated cancers
Prankur Awasthi, Manish Dwivedi, Dhruv Kumar, et al.
Life Sciences (2022) Vol. 313, pp. 121261-121261
Closed Access | Times Cited: 6
EBV Positivity and Programmed Death-ligand 1 Expression in Diffuse Large B-cell Lymphoma: A Systematic Review
Gabriela Anna Barzyk, Vafie Sheriff
Anticancer Research (2020) Vol. 40, Iss. 11, pp. 5951-5968
Open Access | Times Cited: 8
Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
Wenqi Zhang, Yanfeng Fan, Meng Li, et al.
Disease Markers (2021) Vol. 2021, pp. 1-8
Open Access | Times Cited: 7
Programmed cell death-ligand 1 (PD-L1)+ tumour cells and low-reacting programmed cell death 1 (PD1)+ tumour-infiltrating lymphocytes predict poor prognosis in Epstein–Barr virus+ diffuse large B-cell lymphoma
Shoichi Kimura, Yumi Oshiro, Hiromi Iwasaki, et al.
Clinical and Experimental Medicine (2021) Vol. 22, Iss. 3, pp. 411-419
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top